Literature DB >> 31344423

Gut microbiota in phytopharmacology: A comprehensive overview of concepts, reciprocal interactions, biotransformations and mode of actions.

Priyankar Dey1.   

Abstract

The dynamic and delicate interactions amongst intestinal microbiota, metabolome and metabolism dictates human health and disease. In recent years, our understanding of gut microbial regulation of intestinal immunometabolic and redox homeostasis have evolved mainly out of in vivo studies associated with high-fat feeding induced metabolic diseases. Techniques utilizing fecal transplantation and germ-free mice have been instrumental in reproducibly demonstrating how the gut microbiota affects disease pathogenesis. However, the pillars of modern drug discovery i.e. evidence-based pharmacological studies critically lack focus on intestinal microflora. This is primarily due to targeted in vitro molecular-approaches at cellular-level that largely overlook the etiology of disease pathogenesis from the physiological perspective. Thus, this review aims to provide a comprehensive understanding of the key notions of intestinal microbiota and dysbiosis, and highlight the microbiota-phytochemical bidirectional interactions that affects bioavailability and bioactivity of parent phytochemicals and their metabolites. Potentially by focusing on the three major aspects of gut microbiota i.e. microbial abundance, diversity, and functions, I will discuss phytochemical-microbiota reciprocal interactions, biotransformation of phytochemicals and plant-derived drugs, and pre-clinical and clinical efficacies of herbal medicine on dysbiosis. Additionally, in relation to phytochemical pharmacology, I will briefly discuss the role of dietary-patterns associated with changes in microbial profiles and review pharmacological study models considering possible microbial effects. This review therefore, emphasize on the timely and critically needed evidence-based phytochemical studies focusing on gut microbiota and will provide newer insights for future pre-clinical and clinical phytopharmacological interventions.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  3,4-Dihydroxybenzoic (PubChem CID: 72); 8-Prenylnaringenin (PubChem CID: 480764); Alloxan (PubChem CID: 5781); Amygdalin (PubChem CID: 656516); Anthocyanins (PubChem CID: 145858); Anthracene (PubChem CID: 8418); Baicalein (PubChem CID: 5281605); Baicalin (PubChem CID: 64982); Berberine (PubChem CID: 2353); Biotransformation; Butyrate (PubChem CID: 104775); Camptothecin (PubChem CID: 24360); Carbon tetrachloride (PubChem CID: 5943); Carrageenan (PubChem CID: 6850766); Catechin (PubChem CID: 9064); Chebulinic acid (PubChem CID: 72284); Compound K (PubChem CID: 5481990); Curcumin (PubChem CID: 969516); Cyanide (PubChem CID: 5975); Cyanidin-3-glucoside (PubChem CID: 197081); Daidzin (PubChem CID: 107971); Diethylnitrosamine (PubChem CID: 5921); Digoxin (PubChem CID: 2724385); Dihydroberberine (PubChem CID: 10217); Dihydrodaidzein (PubChem CID: 176907); Dihydrodegoxin (PubChem CID: 92217); Ellagic acid (PubChem CID: 5281855); Equol (PubChem CID: 91469); Flavan-3-ol (PubChem CID: 3707243); Flavanone (PubChem CID: 10251); Flavonols (PubChem CID: 11349); Gallic acid (PubChem CID: 370); Ginsenoside Rb1 (PubChem CID: 135398523); Hydroxybenzoic acid (PubChem CID: 7420); Hydroxyhippuric acid (PubChem CID: 450268); Hydroxyphenyl propionc acid (PubChem CID: 10394); Irinotecan (PubChem CID: 60838); Irisolidone (PubChem CID: 5281781); Isoflavone (PubChem CID: 72304); Isorhamnetin (PubChem CID: 5281654); Isoxanthohumol (PubChem CID: 513197); Kakkalide (PubChem CID: 5490351); Lipopolysaccharide (PubChem CID: 11970143); Microbiota; Naringin (PubChem CID: 442428); Nutrition; Obesity; Oleandrin (PubChem CID: 11541511); Pectin (PubChem CID: 441476); Pharmacology; Phenylacetic acid (PubChem CID: 999); Phytochemicals; Pyrogallol (PubChem CID: 1057); Quercetin (PubChem CID: 5280343); Rheinanthrone (PubChem CID: 119396); Rutin (PubChem CID: 5280805); Scopolamine (PubChem CID: 3000322); Sennoside A (PubChem CID: 73111); Streptozotocin (PubChem CID: 29327); Tectoridin (PubChem CID: 5281810); Tectorigenin (PubChem CID: 5281811); Tetrahydrocurcumin (PubChem CID: 124072); Tetrahydrodaidzein (PubChem CID: 53628980); Urolithin A (PubChem CID: 5488186); Vitexin (PubChem CID: 5280441); γ-Valerolactones (PubChem CID: 7921)

Mesh:

Substances:

Year:  2019        PMID: 31344423     DOI: 10.1016/j.phrs.2019.104367

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  33 in total

1.  Comparative analysis of the gut microbiota cultured in vitro using a single colon versus a 3-stage colon experimental design.

Authors:  Jenni Firrman; LinShu Liu; Karley Mahalak; Ceylan Tanes; Kyle Bittinger; Jamshed Bobokalonov; Lisa Mattei; Huanjia Zhang; Pieter Van den Abbeele
Journal:  Appl Microbiol Biotechnol       Date:  2021-03-25       Impact factor: 4.813

Review 2.  Cancer-Associated Microbiota: From Mechanisms of Disease Causation to Microbiota-Centric Anti-Cancer Approaches.

Authors:  Priyankar Dey; Saumya Ray Chaudhuri
Journal:  Biology (Basel)       Date:  2022-05-16

Review 3.  Medicinal Plants and Their Impact on the Gut Microbiome in Mental Health: A Systematic Review.

Authors:  Eva-Maria Pferschy-Wenzig; Manuela R Pausan; Karin Ardjomand-Woelkart; Stefanie Röck; Ramy M Ammar; Olaf Kelber; Christine Moissl-Eichinger; Rudolf Bauer
Journal:  Nutrients       Date:  2022-05-18       Impact factor: 6.706

4.  Superoxide-producing thermostable associate from the small intestines of control and alloxan-induced diabetic rats: quantitative and qualitative changes.

Authors:  R M Simonyan; K V Simonyan; G M Simonyan; H S Khachatryan; M A Babayan; M H Danielyan; L V Darbinyan; M A Simonyan
Journal:  BMC Endocr Disord       Date:  2022-10-18       Impact factor: 3.263

Review 5.  Contribution of Biotransformations Carried Out by the Microbiota, Drug-Metabolizing Enzymes, and Transport Proteins to the Biological Activities of Phytochemicals Found in the Diet.

Authors:  Anna Boronat; Jose Rodriguez-Morató; Gabriele Serreli; Montserrat Fitó; Rachel F Tyndale; Monica Deiana; Rafael de la Torre
Journal:  Adv Nutr       Date:  2021-12-01       Impact factor: 11.567

Review 6.  Potential of the ellagic acid-derived gut microbiota metabolite - Urolithin A in gastrointestinal protection.

Authors:  Małgorzata Kujawska; Jadwiga Jodynis-Liebert
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742

Review 7.  Deciphering the Role of Polyphenols in Sports Performance: From Nutritional Genomics to the Gut Microbiota toward Phytonutritional Epigenomics.

Authors:  Vincenzo Sorrenti; Stefano Fortinguerra; Giada Caudullo; Alessandro Buriani
Journal:  Nutrients       Date:  2020-04-29       Impact factor: 5.717

8.  Toward a Symbiotic Perspective on Public Health: Recognizing the Ambivalence of Microbes in the Anthropocene.

Authors:  Salla Sariola; Scott F Gilbert
Journal:  Microorganisms       Date:  2020-05-16

Review 9.  Role of gut microbiota in identification of novel TCM-derived active metabolites.

Authors:  Tzu-Lung Lin; Chia-Chen Lu; Wei-Fan Lai; Ting-Shu Wu; Jang-Jih Lu; Young-Mao Chen; Chi-Meng Tzeng; Hong-Tao Liu; Hong Wei; Hsin-Chih Lai
Journal:  Protein Cell       Date:  2020-09-15       Impact factor: 14.870

10.  Regulation of GABAA and 5-HT Receptors Involved in Anxiolytic Mechanisms of Jujube Seed: A System Biology Study Assisted by UPLC-Q-TOF/MS and RT-qPCR Method.

Authors:  Liang Chen; Xue Zhang; Chun Hu; Yi Zhang; Lu Zhang; Juntao Kan; Bo Li; Jun Du
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.